

# THE ISSUE

ANTIMICROBIAL RESISTANCE  
IN THE EU EVERY YEAR:



**KILLS**  
33.000 People

**COSTS THE  
ECONOMY**  
€ 1.5 Billion



## CHALLENGES

In the development of new drugs

- 1 Scientific challenges
- 2 Regulatory challenges
- 3 Business challenges



**ACTIONPLAN  
EUROPEAN  
COMMISSION**  
issued in 2011

**IMI NEW DRUGS  
4 BAD BUGS  
PROGRAM**  
issued in 2012

# UNIQUE COLLABO- RATION



IMI established an unprecedented partnership between industry, academia and biotech organizations to combat antibiotic resistance in Europe

## OBJECTIVES

- 1 A self-sustaining antibacterial development network
  - ✓ Expanded research and laboratory networks
  - ✓ Optimal alignment of clinical trials with investigator sites
  - ✓ Clinical and epidemiological data
- 2 Increased efficiency of antimicrobial drug development
  - ✓ Align clinical trials with cutting edge molecular methodologies and trial design
  - ✓ Deliver clinical trials with various candidate compounds from AstraZeneca, Aicuris, Pfizer, Da Volterra.